Scientists are testing a new way to treat a blood condition called Myelodysplastic Syndrome (MDS), which can lead to leukemia. This trial involves patients with a special mutation called IDH2. They usually get a combination of drugs called cedazuridine-decitabine. Now, researchers want to see if adding another drug, enasidenib, makes the treatment better.
The study compares two groups: one gets the usual treatment, and the other gets the usual treatment plus enasidenib. Enasidenib is a medicine that blocks certain enzymes, possibly stopping harmful cells from growing. Each treatment cycle lasts 28 days, and the study will check how well the treatments work and their side effects.
- Participating in this study involves regular visits to the hospital for treatment and tests.
- Some patients may switch treatments based on their response after 6 cycles.
- Potential side effects and risks will be monitored closely during the study.
How understandable was the trial content above?
Hard to understand
Easy to understand